Primary Immune Deficiency and IVIG: A Guide for Newly Diagnosed Patients

July 8, 2026

Receiving a diagnosis of primary immune deficiency (PID), also called primary immunodeficiency disease, can feel overwhelming. You are being told that your immune system has a structural problem that limits its ability to produce the antibodies needed to fight infections. For many patients, that news is followed almost immediately by a recommendation to start immunoglobulin replacement therapy.


This guide is for patients who are newly diagnosed and trying to understand what IVIG treatment involves, what the long-term commitment looks like, and how home infusion therapy fits into the picture. Pharmko has supported PID patients across 22+ states through the full arc of this therapy, from first infusion to long-term maintenance.


What Is Primary Immune Deficiency?


Primary immune deficiency is an umbrella term for a group of conditions in which a component of the immune system, most commonly the ability to produce immunoglobulins (antibodies), is absent, reduced, or dysfunctional. Unlike secondary immune deficiencies caused by medications, HIV, or cancer treatment, PIDs are intrinsic conditions resulting from genetic or developmental problems in immune cell function.


The most common forms of PID include:


  • Common variable immune deficiency (CVID), the most frequently diagnosed adult PID, characterized by low IgG, IgA, and/or IgM and poor vaccine responses
  • X-linked agammaglobulinemia (XLA), typically diagnosed in young males, with near-absent B cells and very low or absent immunoglobulins
  • Selective IgA deficiency, the most common PID overall, though most patients are asymptomatic
  • Specific antibody deficiency, normal total immunoglobulin levels but inability to produce antibodies to specific antigens (e.g., polysaccharide vaccines)
  • Combined immune deficiencies, conditions affecting both B and T cell function, typically more severe


Diagnosis is made through immunoglobulin quantification, vaccine antibody titers, and in some cases lymphocyte subset analysis and genetic testing.


Why IVIG Is Prescribed for PID


In patients with PIDs characterized by low or absent IgG, the immune system cannot produce adequate antibodies to fight bacterial infections. This leads to recurrent, serious infections — particularly pneumonia, sinusitis, and ear infections, that over time can cause permanent lung damage (bronchiectasis), chronic sinusitis, and other complications.


Immunoglobulin replacement therapy, delivered as IVIG (intravenous immunoglobulin) or SCIG (subcutaneous immunoglobulin), replaces the missing antibodies with a concentrated preparation derived from pooled donated plasma. Regular infusions maintain IgG levels above the threshold needed to prevent serious infections, effectively compensating for the immune system's inability to produce its own.


IVIG is not a cure for PID, it does not fix the underlying immune defect. But it is a highly effective long-term management strategy that allows most PID patients to live full, active lives with significantly reduced infection risk.


What to Expect from Your First IVIG Infusions


For newly diagnosed patients, the first few IVIG infusions typically occur in a supervised clinical setting, a physician's infusion suite, hospital outpatient department, or infusion center, where vital signs are monitored and any early reactions can be managed. This period allows your clinical team to:


  • Identify your optimal infusion rate, some patients tolerate rapid infusion well; others require slower rates to avoid headache, fatigue, or chills
  • Determine your IgG response, labs are drawn to confirm your IgG levels are reaching therapeutic range (typically 500–700 mg/dL minimum, often higher)
  • Establish your dosing schedule, most patients receive IVIG every 3 to 4 weeks, though some require more frequent dosing


Once you have tolerated IVIG without significant reactions and your dosing is established, transitioning to home infusion is a natural next step for most patients. Our dedicated guide on IVIG therapy at home covers the home infusion setup process in detail.


IVIG vs SCIG: Which Is Right for You?


Immunoglobulin replacement therapy is available in two routes, intravenous and subcutaneous, and choosing between them is a decision you make with your immunologist based on your lifestyle, vein access, and personal preference.


  • IVIG: monthly or every-3-weeks infusions over 2–4 hours, administered by a nurse; IgG levels fluctuate between doses (peak after infusion, trough before next dose)
  • SCIG: weekly or biweekly self-injections under the skin, smaller volume per session, more stable IgG levels, no nursing visit required after training


Neither approach is clearly superior, outcomes data show both maintain infection protection effectively when IgG targets are met. Many patients on IVIG eventually transition to SCIG once they are comfortable self-administering; others prefer the monthly nursing contact that IVIG provides.


Long-Term Considerations


PID is a lifelong condition. IVIG or SCIG therapy is typically continued indefinitely, stopping treatment leads to IgG decline and return of infection susceptibility within weeks to months. Long-term considerations include:


  • Annual IgG monitoring and dose adjustments as weight, clinical status, or infection frequency changes
  • Infusion-related side effects management, headache, fatigue, and mild systemic reactions are common and manageable
  • Coordination with your immunologist for breakthrough infections, new diagnoses (PID patients have higher rates of autoimmune complications and certain malignancies), and evolving clinical needs


Pharmko's clinical team supports PID patients throughout this long-term journey. Our nurses conduct regular home visits, our pharmacists review labs at each refill cycle, and our 24/7 support line is available when questions arise between scheduled contacts. Know which symptoms should prompt an immediate call and save our after-hours support number before your first home infusion.


Insurance Coverage for IVIG in PID


IVIG for PID is covered by Medicare Part B and most commercial insurance plans when the diagnosis is documented with lab evidence of low IgG and clinical history of recurrent infections. Pharmko manages prior authorization and works with your immunologist to compile the necessary documentation.


For patients with PID who also have autoimmune complications, a common occurrence, see our guide on home infusion for autoimmune diseases for how those additional therapies can be coordinated.


→ Contact Pharmko to start IVIG therapy: 1-877-540-2003 · info@pharmko.com


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More